Business Description
Sopharma AD-Sofia
ISIN : BG11SOSOBT18
Total Employee Number:
6,005Compare
Compare
Traded in other countries / regions
SFA.BulgariaSPH.Poland3JR.Germany IPO Date
2010-03-22Description
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | 2.09 | |||||
Interest Coverage | 7.55 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.16 | |||||
Beneish M-Score | -2.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.9 | |||||
3-Year EBITDA Growth Rate | -12.9 | |||||
3-Year Book Growth Rate | -32.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.51 | |||||
9-Day RSI | 56.39 | |||||
14-Day RSI | 54.48 | |||||
3-1 Month Momentum % | 11.08 | |||||
6-1 Month Momentum % | -8.21 | |||||
12-1 Month Momentum % | -8.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 0.73 | |||||
Cash Ratio | 0.05 | |||||
Days Inventory | 87.85 | |||||
Days Sales Outstanding | 55.69 | |||||
Days Payable | 61.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward Dividend Yield % | 5.65 | |||||
3-Year Average Share Buyback Ratio | -63 | |||||
Shareholder Yield % | -7.72 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 23.92 | |||||
Operating Margin % | 6.3 | |||||
Net Margin % | 5.67 | |||||
EBITDA Margin % | 10.56 | |||||
FCF Margin % | -2.49 | |||||
OCF Margin % | 3.16 | |||||
ROE % | 16.12 | |||||
ROA % | 7.45 | |||||
ROIC % | 9.31 | |||||
3-Year ROIIC % | 8.73 | |||||
ROC (Joel Greenblatt) % | 21.09 | |||||
ROCE % | 16.31 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 9.28 | |||||
Forward PE Ratio | 12.78 | |||||
PE Ratio without NRI | 9.9 | |||||
Shiller PE Ratio | 6.68 | |||||
Price-to-Owner-Earnings | 12 | |||||
PS Ratio | 0.5 | |||||
PB Ratio | 1.94 | |||||
Price-to-Tangible-Book | 2.57 | |||||
Price-to-Operating-Cash-Flow | 41.74 | |||||
EV-to-EBIT | 12.93 | |||||
EV-to-EBITDA | 9.14 | |||||
EV-to-Forward-EBITDA | 6.7 | |||||
EV-to-Revenue | 0.97 | |||||
EV-to-Forward-Revenue | 0.57 | |||||
EV-to-FCF | -38.84 | |||||
Price-to-GF-Value | 0.61 | |||||
Price-to-Projected-FCF | 5.19 | |||||
Price-to-Median-PS-Value | 0.61 | |||||
Price-to-Graham-Number | 1.06 | |||||
| Price-to-Net-Current-Asset-Value | 64 | |||||
Earnings Yield (Greenblatt) % | 7.73 | |||||
FCF Yield % | -3.32 | |||||
Forward Rate of Return (Yacktman) % | -9.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sopharma AD-Sofia Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,354.628 | ||
| EPS (TTM) (€) | 0.207 | ||
| Beta | 1.1044 | ||
| 3-Year Sharpe Ratio | -0.57 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 18.43 | ||
| 14-Day RSI | 54.48 | ||
| 14-Day ATR (€) | 0.092107 | ||
| 20-Day SMA (€) | 1.76975 | ||
| 12-1 Month Momentum % | -8.21 | ||
| 52-Week Range (€) | 1.5 - 2.48 | ||
| Shares Outstanding (Mil) | 528.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sopharma AD-Sofia Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sopharma AD-Sofia Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| EUR 0.052000 Cash Dividend | 2026-07-09 | In 5 days |
Show
Entries
Sopharma AD-Sofia Frequently Asked Questions
What is Sopharma AD-Sofia(FRA:3JR)'s stock price today?
The current price of FRA:3JR is €1.84. The 52 week high of FRA:3JR is €2.48 and 52 week low is €1.50.
When is next earnings date of Sopharma AD-Sofia(FRA:3JR)?
The next earnings date of Sopharma AD-Sofia(FRA:3JR) is .
Does Sopharma AD-Sofia(FRA:3JR) pay dividends? If so, how much?
Sopharma AD-Sofia(FRA:3JR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sopharma AD-Sofia
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers